Keyphrases
Denmark
100%
Population-based Study
100%
Real-world Population
100%
Salvage Regimen
100%
Treatment Survival
100%
Treatment Intensity
100%
Relapsed or Refractory Diffuse Large B-cell Lymphoma
100%
Adjusted Analysis
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Rituximab
28%
Diffuse Large B-cell Lymphoma (DLBCL)
28%
Relapsed or Refractory
28%
Previously Treated
28%
Treatment Impact
28%
Cox Proportional Hazards Model
14%
Remission
14%
Comorbidity
14%
Palliation
14%
Living Alone
14%
Socioeconomic Factors
14%
Treatment Options
14%
Overall Survival
14%
Chemotherapy
14%
Curative Treatment
14%
5-year Survival
14%
High-dose Chemotherapy
14%
Lymphoma
14%
Socioeconomic Position
14%
Multinomial Regression Analysis
14%
Rituximab Era
14%
Factor Intensity
14%
Medicine and Dentistry
Rituximab
100%
Diffuse Large B-Cell Lymphoma
100%
Overall Survival
66%
Autologous Stem Cell Transplantation
66%
Symptomatic Treatment
33%
Identified Patient
33%
Proportional Hazards Model
33%
High Dose Chemotherapy
33%
Immunology and Microbiology
B Cell
100%
Rituximab
100%
Overall Survival
66%
Autologous Stem Cell Transplantation
66%
Comorbidity
33%
Drug Megadose
33%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Rituximab
100%
Overall Survival
66%
Autologous Stem Cell Transplantation
66%
Comorbidity
33%
Drug Megadose
33%